Antibacterial Agents TRIZ Cases

Pyrazine derivatives selectively inhibit the PI 3-kinase gamma isoform, resolving potency and specificity trade-offs for asthma treatment.

Segments the dose into immediate and delayed release parts to sustain therapeutic concentrations without triggering antibacterial activity.

Cysteine residues form covalent bonds creating stable cyclic structures that resist proteolytic degradation while preserving antibacterial efficacy.

Polypeptides bind FR1 regions to block immunoglobulin light chain aggregation, stabilizing pharmaceutical compositions against fibril formation.

Extracted non-proteinaceous compounds from Calanus finmarchicus inhibit antibiotic-resistant pathogens while retaining thermal stability.

Attaching PEG chains to DNA dendrimers prevents nuclease degradation in serum, maintaining therapeutic integrity for drug delivery applications.

Modular pyrimidine-amine structures inhibit c-kit and PDGFR kinases, resolving specificity gaps in treating fibrotic disorders.

Combining fosfomycin with agents like piperacillin-tazobactam overcomes multi-drug resistance by targeting heterogeneous bacterial populations.

Merges three botanical compounds into a single regimen that reduces ACE2 expression to overcome limited antiviral treatment options.

A tetravalent dengue vaccine unit dose delivers live attenuated strains across all serotypes for broad population protection.

Short-chain fatty acids block horizontal gene transfer to reduce antibiotic resistance spread.

Cold extrusion maintains active ingredient stability during production, preventing thermal degradation of pharmaceutical compounds.

Merging 1B7 and 11E6 epitopes into one molecule reduces manufacturing complexity while extending half-life via FcRn binding mutations.

Replacing native receptor binding proteins expands the bactericidal spectrum of phage tail-like bacteriocins against diverse Enterococcus species.

A phenylboronic acid derivative inhibits carbapenem-hydrolyzing class D beta-lactamases.

Supramolecular polymer composition encapsulates hydrophobic materials to form self-healing antimicrobial coatings.

Targeting microbial CutC and CntA enzymes reduces TMAO without affecting human FMO3 activity, avoiding hepatic inflammation.

Overexpressing the endogenous phoP-phoR two-component system in recombinant BCG boosts IFN-gamma production, reducing bacterial burden and pathology.

Replacing complex chemical synthesis, the patent employs oligosaccharyltransferase PglB for efficient conjugation, reducing production time and costs.

Disulfide-linked dimeric adiponectin receptor fragments inhibit ADAM-17 and IDE enzymes to resolve insufficient therapeutic efficacy in diabetes treatment.

Recombinant Evasin-3 from tick saliva binds and inhibits CXC-chemokines, resolving the lack of effective antagonists for treating inflammatory diseases.

Substituted quinoline derivatives inhibit Mycobacterium tuberculosis growth, shortening treatment duration and improving patient compliance.

Inhaled activated protein C targets pulmonary airspaces to inhibit fibrin deposition directly at the site of injury.

Spiroquinoxaline derivatives target RIP1 and RIP3 kinases to block non-apoptotic cell death pathways.

Alginate and gelatin bioinks enable sustained probiotic release through crosslinked scaffolds, resolving localized delivery reliability issues.

Fermented Formula I compounds provide antibacterial activity against multi-drug resistant strains.

Formula I compounds inhibit InhA without KatG activation, treating resistant tuberculosis strains.

Chelating agents bind zinc ions to prevent precipitation with preservatives, maintaining chemical stability while ensuring effective microbial control.

Composite biomaterial combines collagen with hydrophobic organic polymers to enable sustained release of active ingredients.

Screened compounds block Yop protein release to lower virulence while preserving host cell integrity and avoiding general toxicity.

Enhancers mediate antimicrobial agent stability in degrading polyesters, preventing processing deterioration while maintaining biocompatibility.

HMGB1 inhibitors delay toxin B-induced tissue damage, reducing recurrence by protecting intestinal flora from antibiotic disruption.

Deglycosylated MUC1 decoy peptides intercept bacterial flagellin to block adhesion on airway epithelial cells.

Plant-based Acacia nilotica extract replaces chemical agents to synthesize stable silver nanoparticles for antimicrobial wound healing applications.

Bacillus amyloliquefaciens strain 298 controls respiratory pathogens without lung colonization, resolving safety trade-offs in probiotic therapy.

Deleting UL128 and UL130 from cytomegalovirus vectors overcomes narrow epitope recognition limits, enabling durable virologic control.

Novel six-membered heterocycle derivatives inhibit serine proteases with high selectivity.

Inhaled N-chlorotaurine compositions resolve toxicity contradictions by delivering broad-spectrum antimicrobial activity without inducing resistance.

Modified Rv3616c proteins overcome BCG limitations by preventing latent tuberculosis reactivation.

Fusion proteins combine endolysins with peptide stretches to degrade bacterial cell walls.

Benzimidazole compounds target the ATP binding sites in GyrB subunits, resolving antibiotic resistance issues caused by Arg136 mutations.

Synthetic peptides derived from spiny lobster combat multi-drug resistant bacteria through membrane lysis and synergistic antibiotic combinations.

Bi- and polycyclic substituted isoquinoline derivatives inhibit Rho-kinase activity.

Lactococcus lactis C11JN strain overcomes antibiotic resistance by producing composite bioactive compounds that inhibit pathogenic bacteria growth.

pH-dependent polymer coating releases rifaximin in the intestine to reduce systemic side effects and improve patient compliance.

Fluorinated amide compounds disrupt bacterial biofilms, allowing the immune system to clear infections without inducing antibiotic resistance.